Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8003957 | 0.87 | TRPV4 (0.48) | TRPV4HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL31649953 | 0.85 | TRPV4 (0.55) | TRPV4HPGDMAPTALDH1A1KMT2A | |
| SCHEMBL9093802 | 0.82 | TRPV4 (0.58) | TRPV4HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL30545664 | 0.82 | TRPV4 (0.58) | TRPV4HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL23224211 | 0.82 | IMPDH2 (0.60) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL7356053 | 0.80 | CA12 (0.61) | TRPV4MAPTRAB9ANPSR1LMNA | |
| SCHEMBL26073978 | 0.80 | TRPV4 (0.60) | TRPV4MEN1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL6559181 | 0.80 | TRPV4 (0.60) | TRPV4MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL6997419 | 0.79 | TAS1R3 (0.52) | HPGDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL13701787 | 0.78 | ANO1 (0.53) | HPGDMAPTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202960-B1 | METHOD FOR THE PREPARATION OF 2-METHOXY-4-(N-T-BUTYLAMINO-CARBONYL)-BENZENESULFONYL CHLORIDE | SANOFI SYNTHELABO (FR) | 2004-03-10 | — | — | EP | claimed |
| US-6548702-B1 | Sulfonating m-hydroxybenzoic acid; methylation, salt formation, chlorination, reaction with t-butylamine | SANOFI-SYNTHELABO (FR) | 2003-04-15 | — | — | US | claimed |
| EP-1202960-A1 | METHOD FOR THE PREPARATION OF 2-METHOXY-4-(N-T-BUTYLAMINO-CARBONYL)-BENZENESULFONYL CHLORIDE | SANOFI-SYNTHELABO (FR) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005754-A1 | METHOD FOR THE PREPARATION OF 2-METHOXY-4-(N-T-BUTYLAMINO-CARBONYL)-BENZENESULFONYL CHLORIDE | SANOFI-SYNTHELABO (FR) | 2001-01-25 | — | — | WO | claimed |
| EP-2373632-B1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER IP GMBH (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-8859601-B2 | Substituted benzyl and phenylsulfonyl triazolones, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-1794123-B1 | 3-SPIRO-INDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN RECEPTOR LIGAND | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| EP-2373632-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-20110245308-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-06 | — | — | US | disclosed |
| US-7910584-B2 | 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-22 | — | — | US | disclosed |
| US-7910584-B2 | 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-03-22 | — | — | US | disclosed |
| WO-2010063402-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | WO | disclosed |
| EP-1202960-A1 | METHOD FOR THE PREPARATION OF 2-METHOXY-4-(N-T-BUTYLAMINO-CARBONYL)-BENZENESULFONYL CHLORIDE | SANOFI-SYNTHELABO (FR) | 2002-05-08 | — | — | EP | disclosed |
| EP-1196381-A2 | PROCESS FOR THE PREPARATION OF N-(1,1-DIMETHYLETHYL)-4-((5'-ETHOXY-4-CIS-(2-(4-MORPHOLINO)ETHOXY)-2'-OXOSPIRO(CYCLOHEXAN-1,3'-(3H)INDOL)-1'(2'H)-YL)-SULFONYL)-3-METHOXYBENZAMIDE AND ITS SALTS | SANOFI-SYNTHELABO (FR) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005791-A2 | NEW PROCESS FOR THE PREPARATION OF N-(1,1-DIMETHYLETHYL)-4-[[5'-ETHOXY-4-cis-[2-(4-MORFOLINO)ETHOXY]-2'-OXOSPIRO[CYCLOHEXAN-1,3'-[H]INDOL]-1'(2'H)-yl]-SULFONYL]-3-METHOXYBENZAMIDE AND ITS SALTS | SANOFI-SYNTHELABO (FR) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005754-A1 | METHOD FOR THE PREPARATION OF 2-METHOXY-4-(N-T-BUTYLAMINO-CARBONYL)-BENZENESULFONYL CHLORIDE | SANOFI-SYNTHELABO (FR) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005754-A1 | METHOD FOR THE PREPARATION OF 2-METHOXY-4-(N-T-BUTYLAMINO-CARBONYL)-BENZENESULFONYL CHLORIDE | SANOFI-SYNTHELABO (FR) | 2001-01-25 | — | — | WO | disclosed |
| US-6090818-A | CARDIOVASCULAR DISORDERS; ANTISECRETORY AGENTS; OXYTOCIN, VASOPRESSIN ANTAGONIST | SANOFI-SYNTHELABO (FR) | 2000-07-18 | — | — | US | disclosed |
| US-6046341-A | AN ACTIVE DRUG HAVING AFFINITY FOR VASOPRESSIN AND/OR OXYTOCIN RECEPTORS | SANOFI-SYNTHELABO (FR) | 2000-04-04 | — | — | US | disclosed |
| US-5994350-A | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS; RESPIRATORY SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245308-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | CHUK, BRSK2, IKBKE | TRPV4 1672/4885HPGD 1896/4885MAPT 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.